Development of the hematopoetic prostaglandin D synthase inhibitor, GSK3350916A, for the treatment of Duchenne muscular dystrophy GlaxoSmithKline Non-confidential report Name of applicant: Patrick Eidam Reviewed: April, 2016 in Barcelona, Spain